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Abstract 1 
Background 2 
The importance and usefulness of competency frameworks (CFs) in pharmacy professional development 3 
is recognised globally. However, there is no national CF for pharmacists in Japan yet.  4 
Objective 5 
This study was conducted to measure the level of relevance of behavioural statements of the 6 
International Pharmaceutical Federation (FIP) Global Competency Framework (GbCF) to Japanese 7 
foundation-level pharmacy practice, aiming for developing a national framework for foundation-level 8 
pharmacists in Japan. 9 
Methods 10 
A cross-sectional, anonymous, online self-completed survey was conducted during June and July 2018 in 11 
Japan. The questionnaire was adopted from the GbCF, translated into Japanese. A snowballing sampling 12 
approach was used.  The relevance levels of the GbCF items were assessed by using 4-point Likert scales, 13 
and analysed by descriptive and inferential methods. 14 
Results 15 
A total 604 usable responses were included in analyses. High levels of relevance levels were found in two 16 
clusters (‘pharmaceutical public health’ and ‘pharmaceutical care’), while the other two clusters 17 
(‘organisation and management’ and ‘professional/personal’) showed significantly low relevance 18 
(relevance=89.6%, 82.5%, 59.6%, and 67.9%, respectively). The study found little engagement of 19 
academic sector with framework, while industry sector showed the relevance to all clusters evenly. 20 
Regarding years working in sectors, the study found there is no progression of relevance in ‘organisation 21 
and management’ and ‘professional/personal’ competencies during foundation years, which is a worry in 22 
terms of the ability of pharmacists taking the management role transitioning towards advanced level, as 23 
well as very little professional/personal development. 24 
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Conclusions 1 
The study pointed out specific competencies and behaviours which require modifications to adapt the 2 
GbCF into Japanese pharmacy practice environment. This is a key step towards development of a national 3 
framework, illustrating current Japanese foundation-level pharmacy practice compared with global 4 
standards. The findings will be used as a base for developing a framework for foundation-level 5 
pharmacists in Japan. 6 
Keywords 7 
Competency Framework, FIP, GbCF, Continuing Professional Development, CPD, Pharmacy 8 
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Introduction 1 
At an era of rapid demographic and epidemiological transitions as well as accelerated medical and 2 
technological evolution, healthcare environments continuously change and increase the complexity.1, 2 3 
Lifelong learning is essential for pharmacists to attain and maintain essential competencies so as to 4 
ensure the quality of patient care delivery for safe and appropriate use of medicines in patients and 5 
improved public health. Considering such situation across nations, there is a greater attention to 6 
education and training of healthcare professional workforce globally.2-4 7 
Since the concept of competency was introduced in 1960s, competencies are receiving a growing 8 
attention in healthcare professional development.5, 6 The importance and usefulness of competency has 9 
been spread in pharmacy globally. This can be identified from works by the International Pharmaceutical 10 
Federation (FIP) including: the development of the Global Competency Framework (GbCF) in 2012,7  the 11 
publication of the Pharmacy Workforce Development Goals in 2016 addressing the competency 12 
development as one of the thirteen goals,8 and declaring the Nanjing Statements on Pharmacy and 13 
Pharmaceutical Sciences Education in 2017, describing that pharmacists in all sectors and pharmaceutical 14 
scientists need competence to respond to the needs of the public.9  15 
A competency is defined as ‘an underlying characteristic of an individual that is causally related to 16 
effective performance’.10 Competencies embrace knowledge, skills, attitude and behaviours in order for 17 
an individual professional to support their effective and persistent performance.7 Each competency is 18 
accompanied by behavioural statements which describe measurable behaviours that would be observed 19 
when the individual demonstrates the competency.10 20 
A competency framework (CF) therefore is described as a complete set of competencies and associated 21 
behavioural statements that are essential to effective performance in the area of work and practice.11 A 22 
CF can be used as a mapping tool for education development.7 The educational development using a 23 
competency framework is called as competency-based education12, and now globally accepted and 24 
endorsed for education of health professions.13  25 
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The development of pharmacy CFs nationally across all sectors is a key to clear and consistent training 1 
and professional development of pharmacist.14 The World Health Organization (WHO) addresses that ‘the 2 
failure to adopt or develop national competencies has a significant impact on regulators’ ability to ensure 3 
meaningful systems of accreditation, licensure and CPD’.15 Many countries around the world made 4 
endeavours to develop CFs for pharmacists, adopting the FIP GbCF based on their pharmaceutical needs 5 
and responsibilities.16  6 
The FIP GbCF was developed by synthesising documents across nations related to capabilities and 7 
competencies of foundation level pharmacy practice.17 Foundation practice is considered as early years 8 
practice from entry level of licensing.7 In the United Kingdom, the foundation practice is usually within 9 
the first 1,000 days of registered practice, and requires competencies essential across all sectors and 10 
settings.18 A lifelong learning system provided by the Japanese Pharmaceutical Association, a professional 11 
body for pharmacists in Japan, indicates the foundation level practice aiming to be a generalist takes at 12 
least 4 years.19    13 
In Japan, there are 301,323 pharmacists in 2016, working in community pharmacy (57.1%), healthcare 14 
institutions (19.3%), academia (1.7%), industry (13.9%), and public health (2.3%) and others (5.7%).20 15 
Pharmacists in Japan require completing an accredited 6-year initial pharmacy education programme at 16 
one of the Higher Education Institutions in Japan awarded with Bachelor of Pharmacy degree, and pass a 17 
national examination to practice as a qualified pharmacist. The 6-year pharmacy programme is structured 18 
upon 10 ‘professional competencies for pharmacists,’ defined by the Ministry of Education, Culture, 19 
Sports, Science and Technology (MEXT) and the Pharmaceutical Society of Japan.21 The 10 professional 20 
competencies for pharmacists includes (1) professionalism, (2) patient-oriented attitude, (3) 21 
communication skills, (4) interprofessional team-care, (5) basic sciences, (6) medication therapy 22 
management, (7) community health and medical care, (8) research, (9) lifelong learning, and (10) 23 
education and training.  24 
However, there is no national CF for pharmacists currently in Japan. Although 10 competencies are 25 
addressed in pharmacy education core curriculum as a guidance of undergraduate pharmacy education, 26 
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no behavioural statement was accompanied with these competencies.22 Furthermore, there is no 1 
mandate continuing professional development (CPD) system for pharmacists in Japan to continue their 2 
practice.23 This would cause undesirable variety of the quality of pharmaceutical care delivery by 3 
pharmacists due to a lack of effective professional development. There is an urgent need of developing 4 
CFs for pharmacists in Japan, for providing a set of competencies required to be a pharmacist and 5 
delivering better opportunities for individual pharmacists to identify learning gaps in the effective 6 
professional development journey. This will assist improved delivery of pharmaceutical care for patients 7 
and national wellbeing.  8 
Therefore, this study aimed to investigate the applicability of GbCF in a Japanese pharmacy practice 9 
environment as a first step towards developing a national CF for foundation-level pharmacists. Objectives 10 
were to measure the level of relevance of behavioural statements of the GbCF to a Japanese foundation-11 
level pharmacy practice. 12 
 13 
Methods 14 
The study was approved by the Research Ethics Committee Preliminary Review of the Faculty of 15 
Pharmaceutical Sciences, Josai International University, Japan. The objectives were fulfilled by conducting 16 
a cross-sectional anonymous online questionnaire survey between June and July in 2018.  17 
The questionnaire was adopted from the GbCF consisting of 100 behavioural statements in total under 18 
twenty competencies over four clusters, including: (1) Pharmaceutical Public Health (PPH); (2) 19 
Pharmaceutical Care (PC); (3) Organisation and Management (OM); and (4) Professional/Personal (PP). A 20 
forward-back translation process24 was adopted to translate original GbCF into Japanese in order to keep 21 
the validity of the framework. 22 
A web questionnaire survey was developed, using the Qualtrics (Qualtrics XM). The web questionnaire 23 
also included a cover page explaining the background and purpose of the study, electronic consent form, 24 
and seven demographic information of respondents.  25 
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A snowballing sampling approach was used to gather data. This method is a nonprobability sampling 1 
technique, and also known as chain-referral method.25 Contact persons identified by researchers will 2 
recruit further eligible participants within their network. In this study, an invitation letter and a web 3 
address of the questionnaire were emailed to contact persons within the networks of the project team 4 
members (NA and SY). To recruit pharmacists from all sectors, selected contact persons work across 5 
sectors including community pharmacy, hospital, university, public body, and industry. Inclusion criteria 6 
of the sample were (a) registered pharmacists in Japan who have worked in one practice area from day 1 7 
up to 5 years (including those who does not work in patient-facing practice areas), and (b) registered 8 
pharmacists in Japan who have returned from career break or have changed their practice area within 5 9 
years.  10 
Anonymity was promised in the cover letter without any personal information collected. Only 11 
respondents who agreed with participation on an electronic consent form was directed to the web 12 
questionnaire. 13 
Data were directly downloaded into the Statistical Package for Social Science (SPSS) version 25 (IBM) for 14 
quantitative analysis using descriptive and inferential statistics. All data were cleaned manually in the 15 
database with input error and accuracy validated with a random selection of 10% of cases to ensure input 16 
error rates within acceptable limits.  The perceived relevance of each item related to the respondent’s 17 
own scope of practice was rated by four-point Likert scale, which were converted to dichotomous data 18 
(i.e., ‘Not relevant’ and ‘Relevant’) in order to analyse the relevance of each item. A probability level of 19 
p<.05 was used to identify the significance in analysis. 20 
 21 
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Results 1 
Demographics 2 
698 respondents agreed with participation. Of those 698 agreed, 534 fully finished the survey, and 70 3 
partially responded. In total, 604 usable responses were included in analyses. The background 4 
characteristics of the respondents included in analyses were summarised in Table 1.  5 
[Table 1: respondents’ demographics.] 6 
Relevance rating – overall 7 
The levels of relevance differ between clusters (Figure 1). Cluster 1 (PPH) and cluster 2 (PC) had relatively 8 
high levels of relevance of items to foundation-level practice in Japan (PPH ‘relevant’=89.6%; and PC 9 
‘relevant’=82.5%). Cluster 3 (OM) and cluster 4 (PP) showed the significant low relevance of clusters (OM 10 
‘relevant’=59.6%; and PP ‘relevant’=67.9%).  11 
[Figure 1: Relevance rating – overall between clusters.] 12 
Analyses of each item expressed which competencies and behavioural statements were less relevant to 13 
foundation-level practice in Japan, and need modifications for adapting into a Japanese practice 14 
environment (Annex 1 - 4).   15 
Under cluster 2 (PC), an item (2.6(a): patient consultation and diagnosis) was rated more towards ‘not 16 
relevant’, although there was not significant difference between two groups (‘relevant’=45.5%, ‘not 17 
relevant’=54.5%, p=.035). Three items (2.2(b): compounding medicines, 2.5(a): monitor medicines 18 
therapy, and 2.6(c): patient consultation and diagnosis) were rated relatively as low relevant, despite of 19 
their statistically significant relevance (2.2(b): ‘relevant’=66.2%, p<.0001; 2.5(a): ‘relevant’=64.0%, 20 
p<.0001; 2.6(c): ‘relevant’=67.3%, p<.0001). 21 
Data also highlighted the low relevance of cluster 3 (OM) in a foundation-level Japanese pharmacy 22 
practice. Out of six competencies, only one competency (3.5: supply chain and management) was rated 23 
relatively high relevance (cluster average ‘relevant’=75.7%, all items p<.0001). Three items in competency 24 
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3.2 (human resources management) and three in competency 3.4 (procurement) were statistically non-1 
relevant, ranging from 55.4% to 75.6% in ‘not relevant’. 2 
Some items in cluster 4 (PP) were rated as ‘not relevant’ to a foundation-level practice in Japan. For 3 
example, 4.2(a) is about documenting CPD activities, which are recommended practice in Japan, but 4 
these are not mandate (‘not relevant’=60.3%, p<.0001).  More than a half of items in competency 4.5 5 
(quality assurance and research in work place) expressed the tendency towards non-relevance (4.5(a): 6 
‘not relevant’=52.7%, 4.5(c): ‘not relevant’=59.7%, 4.5(d): ‘not relevant’=62.1%, 4.5(g): ‘not 7 
relevant’=62.9%, 4.5(i): ‘not relevant’=59.1%). 8 
Relevance rating – core area of practice 9 
The characteristics of practice between sectors illustrate varying degrees of relevance of competency 10 
clusters (Figure 2). Community and Hospital/Clinics settings have more patient-facing roles compared to 11 
the other sectors, which were shown as high relevance in cluster 1 (PP) (community: ‘relevant’=91.0%, 12 
hospital/clinics: ‘relevant’=89.8%) and cluster 2 (PC) (community: ‘relevant’=84.5%, hospital/clinics: 13 
‘relevant’=82.9%). Figure 2 also shows very low relevance of cluster 3 (OM) in foundation practices in a 14 
hospital/clinics setting (‘relevant’=39.8%).  15 
Furthermore, results express that an academic sector has little engagement in competency framework 16 
(PPH ‘relevant’=61.8%, PC ‘relevant’=49.6%, OM ‘relevant’=44.8%, PP ‘relevant’=61.5%). On the contrary, 17 
industry sector is seemed to be related to all clusters evenly (PPH ‘relevant’=88.9%, PC ‘relevant’=71.6%, 18 
OM ‘relevant’=80.1%, PP ‘relevant’=86.2%). 19 
[Figure 2: Heat map on relevance ratings between sectors] 20 
Relevance rating – Years working in current core area of practice 21 
Figure 3 presents a comparison between years working in current core area of practice with each 22 
competency cluster. A category of ‘more than 6 years working in current core area of practice’ includes 23 
pharmacists who had a career break or child care break within 5 years and came back to practice again. 24 
Within the first 5 years of foundation practice, data shows slight but gradual increase in the degree of 25 
relevance in cluster 1 (PPH) (<1 year to 5 years ‘relevant’=85.5%, 90.2%, 90.3%, 90.9%, 90.9%, 96.4%, 26 
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respectively) and cluster 2 (PC) (<1 year to 5 years ‘relevant’=73.4%, 84.7%, 83.9%, 84.4%, 85.6%, 91.7%, 1 
respectively), but no significant increases in cluster 3 (OM) (<1 year to 5 years ‘relevant’=55.2%, 57.4%, 2 
55.5%, 619%, 66.2%, 58.6%, respectively) and cluster 4 (PP) (<1 year to 5 years ‘relevant’=64.0%, 68.2%, 3 
66.7%, 68.7%, 69.8%, 67.7%, respectively). 4 
[Figure 3: Heat map on relevance ratings between the numbers of years working in current core areas of 5 
practice.] 6 
Relevance rating – Years qualified 7 
Comparing the degrees of relevance of clusters between the numbers of years qualified as pharmacist 8 
(Figure 4), the data illustrates that older respondents engage less in cluster 2 (PC) (0-5 years 9 
‘relevant’=83.6%; 6-10 years ‘relevant’=64.9%; 11-20 years ‘relevant’=82.9%; 21-30 years 10 
‘relevant’=68.6%; and >31 years ‘relevant’=46.0%).  11 
[Figure 4: Heat map on relevance ratings between the numbers of years qualified as pharmacist] 12 
Discussion 13 
This is the first study investigated the applicability of the GbCF in a Japanese pharmacy practice 14 
environment.  15 
The study showed the low levels of relevance of organisation and management competencies in a 16 
foundation pharmacy practice in Japan. Foundation-level pharmacists in Japan are unlikely to engage 17 
with the human resources management, and not often get any support for gaining these competencies at 18 
foundation level. Figure 3 also illustrates that there is no increase in the degree of relevance of practice 19 
related to organisation and management during the foundation practice period, indicating that 20 
pharmacists unable to appreciate practical opportunities to develop organisation and management 21 
competencies. This causes a worry for their career paths when they are promoted or apply for the 22 
management role. At advanced level of practice, pharmacy practitioners increasingly contribute to 23 
management, along with leadership, education and training, research and progressing working 24 
relationships.26 This has been featured in the advanced level competency frameworks developed in Great 25 
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Britain27 and Australia28. For seamless transition from foundation to advanced level practice, these 1 
organisation and management competencies require being instilled at foundation level. Support and 2 
training for developing these competencies will be essential to advance their career paths. 3 
The study also revealed that some aspects of procurements related to costing of products were not 4 
relevant to a foundation level practice in Japan. These are often carried out by the advanced level 5 
practitioners or at a company/hospital level in Japan, which is consistent with the present results. One 6 
item in the procurements competency, an item 3.4(c) related to linkage between procurement to 7 
formulary was indicated as non-relevance significantly. The Japanese government is now encouraging to 8 
develop local formularies for safer, more radical and cost-effective use of medicines.29 Therefore, the 9 
item needs to be considered for future development. 10 
The low level of relevance in cluster 4 (professional/personal) illustrates more works to be done for on-11 
going professional development during foundation-level practice in Japan. There is no mandate CPD to 12 
keep registration as a pharmacist in Japan,23 which led to the low level of documentation of CPD activities 13 
in this study. Documenting CPD activities is a key part of CPD reflective cycle, which needs to be instilled 14 
and developed during undergraduate education and foundation-level practice. Figure 3 also showed no 15 
progression of relevance in cluster 4 during their foundation-level practice years. This is also consistent 16 
with the need of structured CPD system using competency framework showing their clear career paths. 17 
Foundation-level pharmacists expressed the low engagement with many aspects of quality assurance and 18 
research in work place. This raises a worry related to research skills of foundation-level pharmacists, as 19 
well as continuous improvement and advancement of practice. Enquiry-driven and evidence-based 20 
practice is a key to providing safe and effective pharmaceutical care.  21 
Figure 2 illustrates different levels of engagement with the GbCF between sectors. Academic sectors have 22 
little relevance to the framework, while the industry sector engages with the framework across all 23 
clusters evenly. Working conditions of academic pharmacy workforce in Japan could have affected the 24 
results. Academics in pharmacy in Japan mostly work exclusively in a university, not sharing their working 25 
time in other clinical positions. This might cause disconnection with clinical competencies such as 26 
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pharmaceutical public health and pharmaceutical care competencies. This indicates that wording may 1 
need slight changes so that pharmacists in academic sectors would be able to relate themselves in the 2 
use of framework.  3 
Figure 4 pointed out that people qualified as pharmacist more than 31 years very little engagement in 4 
pharmaceutical care compared with the others. It may indicate that concept of pharmaceutical care was 5 
not introduced well in this population. The concept of pharmaceutical care is first developed in hospital 6 
sector in Japan and now grown popular in community sector. Developing and maintaining pharmaceutical 7 
care competencies as pharmacist at the foundation-level practice, when coming back to practice after 8 
career break, or changing sectors. Identifying learning gaps through competency framework is helpful 9 
step to reflect their practice and improve them.  10 
Methods that this study undertook are relevant to all countries where have not developed their own 11 
national CFs for pharmacists. Considering the importance and usefulness of CFs for pharmacy 12 
professional development as well as resources available, it is reasonable and thoughtful to adapt and 13 
adopt the GbCF for their development. A key for the successful development of the CF for individual 14 
country should be consideration of country level practice based on their health needs. For this, the 15 
methods that the present study undertook can be a first step for country level CFs for pharmacists. 16 
It is important to note limitations of the study, including generalisability, sample size and self-completed 17 
questionnaire use. Findings of the study may not be generalizable due to the use of snowballing sampling 18 
methods. Further, sample size is not big enough to express explicit sector- and other categorical levels 19 
comparisons. In addition, the use of self-completed questionnaire is often limited for actual behavioural 20 
measurement. Therefore, there is a need of caution to interpret the results of the study. 21 
Future works include the consensus development panel for developing a daft framework for foundation-22 
level pharmacists in Japan from the results of the study, then validation of the draft framework, which 23 
will be quality assured by expert panel at the end. Lastly, for advancing pharmacy profession globally, the 24 
review and updates of the GbCF7 would be another work to be considered as the roles and 25 
responsibilities of pharmacists have been advanced and evolved in many countries.   26 
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Conclusions 1 
This is the first study that investigated the applicability of the GbCF in a Japanese pharmacy practice 2 
environment. The study allowed to point out specific competencies and behavioural statements which 3 
needs modification to adapt the GbCF into Japanese specific pharmacy practice, through investigating the 4 
levels of relevance of items in the framework. The study was a key first step towards development of 5 
competency framework for a foundation-level pharmacists in Japan. Findings of the study illustrate 6 
current foundation-level pharmacy practice in Japan compared with global standards. Further, these 7 
findings will be used as a base for developing framework, which will assist improving national health of 8 
Japanese population through helping improve and advance professional development of pharmacists 9 
with evidence-based tool.  10 
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Tables 1 
Table 1: Respondents’ demographics 2 
Gender Male 304 (50.3%) 
Female 277 (45.9%) 
Don’t want to answer 23 (3.8%) 
Age Mean 28.53 yo (SD: 5.18, range: 21 – 74) 
Years qualified Mean 3.64 years (SD: 5.00, range: 0 – 43) 
Years working in current core area of practice Mean 2.68 years (SD: 3.25, range: 0 – 35) 
Current core area of 
practice 
Community 480 (79.5%) 
Hospital/Clinics 74 (12.3%) 
Education & research 18 (3.0%) 
Industry 9 (1.5%) 
Others* 23 (3.8%) 
Previous work experience in other practice area 89 (14.7%) 
*Note: Others includes regulatory and public health organisations, pharmaceutical journalist, and no-
clarifications. 
 3 
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Figures 
Figure 1: Relevance rating – overall between clusters 
 
 
 
Figure 2: Heat map on relevance ratings between sectors [Using colour for the figure] 
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Figure 3: Heat map on relevance ratings between the numbers of years working in current core areas of practice [Using 
colour for the figure] 
 
 
 
Figure 4: Heat map on relevance ratings between the numbers of years qualified as pharmacist [Using colour for the figure] 
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Appendices 
Annex 1: Relevance ratings – cluster 1 pharmaceutical public health 
Cluster Competency Behavioural statements Total N 
Not relevant Relevant 
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(a)   Assess the primary healthcare needs 
(taking into account the cultural and social 
setting of the patient) 
599 107 17.9 492 81.5 <.0001 
(b)   Advise on health promotion, disease 
prevention and control, and healthy lifestyle 
600 56 9.3 544 90.7 <.0001 
Average 1199 163 13.6 1036 86.4   
1
.2
 M
ed
ic
in
es
 In
fo
rm
at
io
n
 a
n
d
 
ad
vi
ce
 
(a)   Counsel population on the safe and 
rational use of medicines and devices 
(including the selection, use, contraindications, 
storage, and side effects of non-prescription 
and prescription medicines) 
602 26 4.3 576 95.7 <.0001 
(b)   Identify sources, retrieve, evaluate, 
organise, assess and disseminate relevant 
medicines information according to the needs 
of patients and clients and provide appropriate 
information 
602 61 10.1 541 89.9 <.0001 
Average 1204 87 7.2 1117 92.8 
  Cluster Average 2403 250 10.4 2153 89.6 
 
Annex 2: Relevance ratings – cluster 2 pharmaceutical care 
Cluster Competency Behavioural statements Total N 
Not relevant Relevant 
p 
Count % Count % 
C
lu
st
er
 2
: P
h
ar
m
ac
eu
ti
ca
l C
ar
e
 
2
.1
 A
ss
es
sm
en
t 
o
f 
m
ed
ic
in
es
 
(a)   Appropriately select medicines (e.g. 
according to the patient, hospital, 
government policy, etc.) 
569 51 9.0 518 91.0 <.0001 
(b)   Identify, prioritise and act upon 
medicine-medicine interactions; 
medicine-disease interactions; medicine-
patient interactions; medicines-food 
interactions 
569 36 6.3 533 93.7 <.0001 
Average 1138 87 7.6 1051 92.4   
2
.2
 C
o
m
p
o
u
n
d
in
g 
m
e
d
ic
in
es
 (a)   Prepare pharmaceutical medicines 
(e.g. extemporaneous, cytotoxic 
medicines), determine the requirements 
for preparation (calculations, appropriate 
formulation, procedures, raw materials, 
equipment etc.) 
569 115 20.2 454 79.8 <.0001 
(b)   Compound under the good 
manufacturing practice for 
pharmaceutical (GMP) medicines 
568 192 33.8 376 66.2 <.0001 
Average 1137 307 27.0 830 73.0   
2
.3
 D
is
p
en
si
n
g 
(a)   Accurately dispense medicines for 
prescribed and/or minor ailments and 
monitor the dispense (re-checking the 
medicines) 
568 24 4.2 544 95.8 <.0001 
(b)   Accurately report defective or 
substandard medicines to the 
appropriate authorities 
569 154 27.1 415 72.9 <.0001 
(c)   Appropriately validate prescriptions, 
ensuring that prescriptions are correctly 
interpreted and legal 
567 31 5.5 536 94.5 <.0001 
(d)   Dispense devices (e.g. inhaler or a 
blood glucose meter) 
567 146 25.7 421 74.3 <.0001 
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(e)   Document and act upon dispensing 
errors 
568 64 11.3 504 88.7 <.0001 
(f)    Implement and maintain a 
dispensing error reporting system and a 
‘near misses’ reporting system 
568 87 14.4 481 79.6 <.0001 
(g)   Label the medicines (with the 
required and appropriate information) 
568 31 5.5 537 94.5 <.0001 
(h)   Learn from and act upon previous 
‘near misses’ and ‘dispensing errors’ 
568 29 5.1 539 94.9 <.0001 
Average 4543 566 12.5 3977 87.5   
2
.4
 M
ed
ic
in
es
 
(a)   Advise patients on proper storage 
conditions of the medicines and ensure 
that medicines are stored appropriately 
(e.g. humidity, temperature, expiry date, 
etc.) 
567 29 5.1 538 94.9 <.0001 
(b)   Appropriately select medicine 
formulation and concentration for minor 
ailments (e.g. diarrhoea, constipation, 
cough, hay fever, insect bites, etc.) 
567 127 22.4 440 77.6 <.0001 
(c)   Ensure appropriate medicines, route, 
time, dose, documentation, action, form 
and response for individual patients 
567 74 13.1 493 86.9 <.0001 
(d)   Package medicines to optimise 
safety (ensuring appropriate re-packaging 
and labelling of the medicines) 
567 95 16.8 472 83.2 <.0001 
Average 2268 325 14.3 1943 85.7   
2
.5
 M
o
n
it
o
r 
m
ed
ic
in
es
 t
h
er
ap
y (a)   Apply guidelines, medicines 
formulary system, protocols and 
treatment pathways 
564 203 36.0 361 64.0 <.0001 
(b)   Ensure therapeutic medicines 
monitoring, impact and outcomes 
(including objective and subjective 
measures) 
564 139 24.6 425 75.4 <.0001 
(c)   Identify, prioritise and resolve 
medicines management problems 
(including errors) 
564 113 20.0 451 80.0 <.0001 
Average 1692 455 26.9 1237 73.1   
2
.6
 P
at
ie
n
t 
co
n
su
lt
at
io
n
 a
n
d
 d
ia
gn
o
si
s 
(a)   Apply first aid and act upon 
arranging follow-up care 
565 308 54.5 257 45.5 0.035 
(b)   Appropriately refer 566 79 14.0 487 86.0 <.0001 
(c)   Assess and diagnose based on 
objective and subjective measures 
565 185 32.7 380 67.3 <.0001 
(d)   Discuss and agree with the patients 
the appropriate use of medicines, taking 
into account patients’ preferences 
566 93 16.4 473 83.6 <.0001 
(e)   Document any intervention (e.g. 
document allergies, medicines and food, 
in patient medicines history) 
566 35 6.2 531 93.8 <.0001 
(f)    Obtain, reconcile, review, maintain 
and update relevant patient medication 
and diseases history 
566 38 6.7 528 93.3 <.0001 
Average 3394 738 21.7 2656 78.3 
  
Cluster average 14172 2478 17.5 11694 82.5 
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Annex 3: Relevance ratings – cluster 3 organisation and management 
Cluster Competency Behavioural statements Total N 
Not relevant Relevant 
p 
Count % Count % 
C
lu
st
er
 3
: O
rg
an
is
at
io
n
 a
n
d
 M
an
ag
em
en
t 
3
.1
 B
u
d
ge
t 
an
d
 
re
im
b
u
rs
em
en
t 
(a)   Acknowledge the organisational 
structure 
549 184 33.5 365 66.5 <.0001 
(b)   Effectively set and apply budgets 549 308 56.1 241 43.9 0.005 
(c)   Ensure appropriate claim for the 
reimbursement 
548 193 35.2 355 64.8 <.0001 
(d)   Ensure financial transparency 548 308 56.2 240 43.8 0.004 
(e)   Ensure proper reference sources for 
service reimbursement 
549 283 52.1 263 47.9 0.348 
Average 2743 1276 46.5 1464 53.4   
3
.2
 H
u
m
an
 R
es
o
u
rc
es
 m
an
ag
em
en
t 
(a)   Demonstrate organisational and 
management skills (e.g. know, understand 
and lead on medicines management, risk 
management, self management, time 
management, people management, project 
management, policy management) 
549 252 45.9 297 54.1 0.06 
(b)   Identify and manage human resources 
and staffing issues 
549 324 59.0 225 41.0 <.0001 
(c)   Participate, collaborate, advise in 
therapeutic decision-making and use 
appropriate referral in a multi-disciplinary 
team 
549 247 45.0 302 55.0 0.021 
(d)   Recognise and manage the potential of 
each member of the staff and utilise systems 
for performance management (e.g. carry out 
staff appraisals) 
549 313 57.0 236 43.0 0.001 
(e)   Recognise the value of the pharmacy 
team and of a multidisciplinary team 
549 244 44.4 305 55.6 0.01 
(f)    Support and facilitate staff training and 
continuing professional development 
549 323 58.8 226 41.2 <.0001 
Average 3294 1703 51.7 1591 48.3   
3
.3
 Im
p
ro
ve
m
en
t 
o
f 
se
rv
ic
e 
(a)   Identify and implement new services 
(according to local needs) 
549 244 44.4 305 55.6 0.01 
(b)   Resolve, follow up and prevent 
medicines related problems 
549 160 29.1 389 70.9 <.0001 
Average 1098 404 36.8 694 63.2   
3
.4
 P
ro
cu
re
m
en
t 
(a)   Access reliable information and ensure 
the most cost-effective medicines in the right 
quantities with the appropriate quality 
549 156 28.4 393 71.6 <.0001 
(b)   Develop and implement contingency 
plan for shortages 
549 156 28.4 393 71.6 <.0001 
(c)   Efficiently link procurement to formulary, 
to push/pull system (supply chain 
management) and payment mechanisms 
549 304 55.4 245 44.6 0.013 
(d)   Ensure there is no conflict of interest 549 187 34.1 362 65.9 <.0001 
(e)   Select reliable supplies of high-quality 
products (including appropriate selection 
process, cost effectiveness, timely delivery) 
549 225 41.0 324 59.0 <.0001 
(f)    Supervise procurement activities 549 320 58.3 229 41.7 <.0001 
(g)   Understand the tendering methods and 
evaluation of tender bids 
549 415 75.6 134 24.4 <.0001 
Average 3843 1763 45.9 2080 54.1   
3
.5
 
Su
p
p
ly
 
ch
ai
n
 
an
d
 
m
an
ag
e
m
en
t (a)   Demonstrate knowledge in store 
m dicines to minimise errors and maximise 
accuracy 
549 88 16.0 461 84.0 <.0001 
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(b)   Ensure accurate verification of rolling 
stocks 
549 62 11.3 487 88.7 <.0001 
(c)   Ensure effective stock management and 
running of service with the dispensary 
549 64 11.7 485 88.3 <.0001 
(d)   Ensure logistics of delivery and storage 549 191 34.8 358 65.2 <.0001 
(e)   Implement a system for documentation 
and record keeping 
549 184 33.5 365 66.5 <.0001 
(f)    Take responsibility for quantification of 
forecasting 
549 210 38.3 339 61.7 <.0001 
Average 3294 799 24.3 2495 75.7   
3
.6
 W
o
rk
p
la
ce
 m
an
ag
em
en
t 
(a)   Address and manage day to day 
management issues 
549 179 32.6 370 67.4 <.0001 
(b)   Demonstrate the ability to take accurate 
and timely decisions and make appropriate 
judgements 
549 156 28.4 393 71.6 <.0001 
(c)   Ensure the production schedules are 
appropriately planned and managed 
549 187 34.1 362 65.9 <.0001 
(d)   Ensure the work time is appropriately 
planned and managed 
549 186 33.9 363 66.1 <.0001 
(e)   Improve and manage the provision of 
pharmaceutical services 
549 186 33.9 363 66.1 <.0001 
(f)    Recognise and manage pharmacy 
resources (e.g. financial, infrastructure) 
549 261 47.5 288 52.5 0.267 
Average 3294 1155 35.1 2139 64.9 
  
Cluster average 17566 7100 40.4 10463 59.6 
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Annex 4: Relevance ratings – cluster 4 professional/personal 
Cluster Competency Behavioural statements Total N 
Not relevant Relevant 
p 
Count % Count % 
C
lu
st
er
 4
: P
ro
fe
ss
io
n
al
/P
er
so
n
al
 
4
.1
 C
o
m
m
u
n
ic
at
io
n
 s
ki
lls
 
(a)   Communicate clearly, precisely and 
appropriately while being a mentor or tutor 
537 113 21.0 424 79.0 <.0001 
(b)   Communicate effectively with health and 
social care staff, support staff, patients, carer, 
family relatives and clients/customers, using lay 
terms and checking understanding 
535 66 12.3 469 87.7 <.0001 
(c)   Demonstrate cultural awareness and 
sensitivity 
536 184 34.3 352 65.7 <.0001 
(d)   Tailor communications to patient needs 536 33 6.2 503 93.8 <.0001 
(e)   Use appropriate communication skills to build, 
report and engage with patients, health and social 
care staff and voluntary services (e.g. verbal and 
non-verbal) 
537 85 15.8 452 84.2 <.0001 
Average 2681 481 17.9 2200 82.1   
4
.2
 C
o
n
ti
n
u
in
g 
P
ro
fe
ss
io
n
al
 
D
ev
el
o
p
m
en
t 
(C
P
D
) 
(a)   Document CPD activities 537 324 60.3 213 39.7 <.0001 
(b)   Engage with students/interns/residents 537 243 45.3 294 54.7 0.031 
(c)   Evaluate currency of knowledge and skills 537 224 41.7 313 58.3 <.0001 
(d)   Evaluate learning 536 219 40.9 317 59.1 <.0001 
(e)   Identify if expertise needed outside the scope 
of knowledge 
535 239 44.7 296 55.3 0.015 
(f)    Identify learning needs 536 218 40.7 318 59.3 <.0001 
(g)   Recognise own limitations and act upon them 536 113 21.1 423 78.9 <.0001 
(h)   Reflect on performance 536 103 19.2 433 80.8 <.0001 
Average 4290 1683 39.2 2607 60.8   
4
.3
 L
eg
al
 a
n
d
 r
eg
u
la
to
ry
 p
ra
ct
ic
e
 
(a)   Apply and understand regulatory affairs and 
the key aspects of pharmaceutical registration and 
legislation 
537 121 22.5 416 77.5 <.0001 
(b)   Apply knowledge in relation to the principals 
of business economics and intellectual property 
rights including the basics of patent interpretation 
537 253 47.1 284 52.9 0.195 
(c)   Be aware of and identify the new medicines 
coming to the market 
536 133 24.8 403 75.2 <.0001 
(d)   Comply with legislation for drugs with the 
potential for abuse 
536 57 10.6 479 89.4 <.0001 
(e)   Demonstrate knowledge in marketing and 
sales 
536 284 53.0 252 47.0 0.181 
(f)    Engage with health and medicines policies 535 178 33.3 357 66.7 <.0001 
(g)   Understand the steps needed to bring a 
medicinal product to the market including the 
safety, quality, efficacy and pharmacoeconomic 
assessments of the product 
536 186 34.7 350 65.3 <.0001 
Average 3753 1212 32.3 2541 67.7   
4
.4
 P
ro
fe
ss
io
n
al
 a
n
d
 e
th
ic
al
 p
ra
ct
ic
e
 
(a)   Demonstrate awareness of local /national 
codes of ethics 
536 200 37.3 336 62.7 <.0001 
(b)   Ensure confidentiality (with the patient and 
other healthcare professionals) 
535 20 3.7 515 96.3 <.0001 
(c)   Obtain patient consent (it can be implicit on 
occasion) 
536 36 6.7 500 93.3 <.0001 
(d)   Recognise own professional limitations 537 37 6.9 500 93.1 <.0001 
(e)   Take responsibility for own action and for 
patient care 
536 31 5.8 505 94.2 <.0001 
Average 2680 324 12.1 2356 87.9   
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4
.5
 Q
u
al
it
y 
as
su
ra
n
ce
 a
n
d
 r
es
ea
rc
h
 in
 w
o
rk
 p
la
ce
 
(a)   Apply research findings and understand the 
benefit risk (e.g. pre-clinical, clinical trials, 
experimental clinical-pharmacological research 
and risk management) 
535 282 52.7 253 47.3 0.226 
(b)   Audit quality of service (ensure that they 
meet local and national standards and 
specifications) 
535 234 43.7 301 56.3 0.004 
(c)   Develop and implement Standing Operating 
Procedures (SOPs) 
534 319 59.7 215 40.3 <.0001 
(d)   Ensure appropriate quality control tests are 
performed and managed appropriately 
535 332 62.1 203 37.9 <.0001 
(e)   Ensure medicines are not counterfeit and 
quality standards 
536 237 44.2 299 55.8 0.008 
(f)    Identify and evaluate evidence-base to 
improve the use of medicines and services 
536 228 42.5 308 57.5 0.001 
(g)   Identify, investigate, conduct, supervise and 
support research at workplace (enquiry-driven 
practice) 
536 337 62.9 199 37.1 <.0001 
(h)   Implement, conduct and maintain a reporting 
system of pharmacovigilance (e.g. report Adverse 
Drug Reactions) 
533 215 40.3 318 59.7 <.0001 
(i)     Initiate and implement audit and research 
activities 
535 316 59.1 219 40.9 <.0001 
Average 4815 2500 51.9 2315 48.1   
4
.6
 S
el
f-
m
an
ag
em
en
t 
(a)   Apply assertiveness skills (inspire confidence) 535 102 19.1 433 80.9 <.0001 
(b)   Demonstrate leadership and practice 
management skills, initiative and efficiency 
535 179 33.5 356 66.5 <.0001 
(c)   Document risk management (e.g. critical 
incidents) 
535 117 21.9 418 78.1 <.0001 
(d)   Ensure punctuality 535 10 1.9 525 98.1 <.0001 
(e)   Prioritise work and implement innovative 
ideas 
535 92 17.2 443 82.8 <.0001 
Average 2675 500 18.7 2175 81.3 
  Cluster average 20894 6700 32.1 14194 67.9 
 
